Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of BH011 injection combined with sequential intravesical gemcitabine for BCG-failed high-risk non-muscle-invasive bladder cancer
CTR20253473Phase 2Active
- Sponsor
- Zhuhai Beihai Biotech
- Start
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of BH011, gemcitabine in bladder cancer, non-muscle-invasive bladder cancer (NMIBC), sponsored by Zhuhai Beihai Biotech. Started Aug 2025; status: active.
02
Drugs
BH011gemcitabine
03
Conditions
bladder cancernon-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on CTR20253473.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253473.